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Inhibition of DNA2 nuclease as a therapeutic strategy
targeting replication stress in cancer cells
S Kumar1,7, X Peng2,3,7, J Daley4, L Yang2,8, J Shen2, N Nguyen5, G Bae5, H Niu4,5,9, Y Peng2, H-J Hsieh2, L Wang2, C Rao6, CC Stephan5,
P Sung4, G Ira1 and G Peng2
Replication stress is a characteristic feature of cancer cells, which is resulted from sustained proliferative signaling induced
by activation of oncogenes or loss of tumor suppressors. In cancer cells, oncogene-induced replication stress manifests as
replication-associated lesions, predominantly double-strand DNA breaks (DSBs). An essential mechanism utilized by cells to repair
replication-associated DSBs is homologous recombination (HR). In order to overcome replication stress and survive, cancer cells
often require enhanced HR repair capacity. Therefore, the key link between HR repair and cellular tolerance to replication-
associated DSBs provides us with a mechanistic rationale for exploiting synthetic lethality between HR repair inhibition and
replication stress. DNA2 nuclease is an evolutionarily conserved essential enzyme in replication and HR repair. Here we demonstrate
that DNA2 is overexpressed in pancreatic cancers, one of the deadliest and more aggressive forms of human cancers, where
mutations in the KRAS are present in 90–95% of cases. In addition, depletion of DNA2 significantly reduces pancreatic cancer cell
survival and xenograft tumor growth, suggesting the therapeutic potential of DNA2 inhibition. Finally, we develop a robust high-
throughput biochemistry assay to screen for inhibitors of the DNA2 nuclease activity. The top inhibitors were shown to be
efficacious against both yeast Dna2 and human DNA2. Treatment of cancer cells with DNA2 inhibitors recapitulates phenotypes
observed upon DNA2 depletion, including decreased DNA double strand break end resection and attenuation of HR repair. Similar
to genetic ablation of DNA2, chemical inhibition of DNA2 selectively attenuates the growth of various cancer cells with oncogene-
induced replication stress. Taken together, our findings open a new avenue to develop a new class of anticancer drugs by targeting
druggable nuclease DNA2. We propose DNA2 inhibition as new strategy in cancer therapy by targeting replication stress, a
molecular property of cancer cells that is acquired as a result of oncogene activation instead of targeting currently undruggable
oncoprotein itself such as KRAS.
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INTRODUCTION
The finding that poly(ADP-ribose) polymerase inhibitors, a new
class of DNA repair inhibitors, specifically kill cancer cells with
BRCA1 or BRCA2 mutations but are less cytotoxic to normal cells
highlighted the promise of DNA repair inhibitors for targeted
cancer treatment.1,2 This finding also provides proof of the
principle that synthetic lethality interactions in the DNA repair
network can be exploited for targeted cancer therapy. Early in the
process of tumorigenesis, genetic alterations such as activation of
oncogenes and loss of tumor-suppressor genes are implicated in
inducing replication stress by providing premalignant cells with
excessive growth signals.3,4 In cancer cells, oncogene-induced
replication stress manifests as a high level of DNA double-strand
breaks (DSBs) because of stalling and collapse of DNA replication
forks.5,6 A marked increase of replication stress and spontaneous
DNA damage in cancer cells, which renders them more dependent
on DNA repair for survival.7 Among all DNA repair pathways,
homologous recombination (HR)-mediated DNA repair is an
essential mechanism utilized by cancer cells to repair
replication-associated DSBs and thereby to overcome replication
stress and survive. The key link between HR repair and cellular
tolerance to replication-associated DSBs provides us with a
mechanistic rationale for exploiting synthetic lethality between
HR repair inhibition and replication stress in cancer cells.
Moreover, owing to their hyper-proliferative state, cancer
cells are more vulnerable to killing by DNA-damaging
agents. Common cancer treatment strategies use untargeted
radiomimetic chemotherapy or radiotherapy that induce a broad
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range of DNA lesions including DSBs. The ability of cancer cells to
repair DNA damage lowers therapeutic efficacy, thus the
simultaneous use of a DNA repair inhibitor holds great promise
in sensitizing cancer cells to conventional chemo/radiotherapy.
Inhibitors that target enzymes mediating base excision repair,
nucleotide excision repair and other DNA repair pathways have
been developed and are being evaluated in clinical trials.8–10
Therefore, identification of new HR repair inhibitors can open new
avenues to cancer therapies.4,11–15
An evolutionarily conserved protein DNA2 possesses 5′ flap
endonuclease and 3′–5′ helicase activities and it has an important
role in DNA damage repair, HR and DNA replication. The nuclease
activity of DNA2 has several well-documented cellular functions,
whereas the biological role of its helicase activity remains
enigmatic. Specifically, DNA2 mediates the resection of the 5′
strand at DNA DSB ends,16–23 an early step in HR, and also at
stalled and regressed replication forks.24,25 Dna2 in fungi
processes long 5′ DNA flaps during the maturation of Okazaki
fragments in lagging strand DNA synthesis,26,27 whereas human
DNA2 (hDNA2) has an essential but as yet undefined role in DNA
replication.28 hDNA2 has an additional function in mitochondrial
DNA maintenance.29 Finally, the unstructured and regulatory
N-terminal domain of yeast Dna2 (yDna2) was recently shown to
regulate DNA damage response by activating the Mec1 kinase
(Mec1 is orthologus to human DNA damage checkpoint kinase
ATR).30 Among these important biological functions of DNA2,
the nucleolytic processing of the 5′ strands at spontaneous DSBs
or regressed replication forks seems to be the most relevant in
alleviating replication stress. Consistent with this notion, Dna2 is
overexpressed via gene duplication in yeast upon replication
stress caused by the mec1-21 mutation.31 Interestingly, similar to
this observation in yeast cells, studies from our group and others
have demonstrated that DNA2 is overexpressed in a broad
spectrum of malignancies including breast cancer, ovarian cancer,
lung cancer, prostate cancer, glioblastoma, pancreatic cancer,
leukemia, colon cancer, melanoma, Lynch syndrome and heredi-
tary nonpolyposis colorectal cancer.32–34 DNA2 overexpression is
needed for the tolerance of increased replication stress induced
by oncogene activation such as H-Ras or cyclin E in osteosarcoma
and breast cancer cells, and partial depletion of DNA2 reduces the
tumorigenicity of breast cancer cells.33 These results have raised
the prospect of targeting DNA2 in cancer therapy.
As the increased nuclease activity of DNA2 is required in yeast
and cancer cells to overcome replication stress and DNA damage,
for the first time, we developed a robust biochemistry-based
screening method for chemical inhibitors of DNA2. We conducted
initial screen with nearly 50 000 compounds and we tested
efficacy of several candidate inhibitors in pancreatic and
breast cancer cell lines with oncogene-induced replication
stress. Treatment of cancer cells with the top DNA2 inhibitor
recapitulates many phenotypes observed upon DNA2 depletion,
and attenuates the growth of various cancer cells. Taken together,
in this study, we developed a feasible high-throughput chemical
screen assay to identify novel DNA repair inhibitors and more
importantly we provided a new synthetic lethal strategy based on
inhibition of HR repair by DNA2 inhibitors in cancer cells with
oncogene-induced replication stress.
RESULTS
Sensitivity of pancreatic cancer cells to DNA2 depletion
Pancreatic cancer is particularly deadly because of the lack of an
effective treatment regimen. Here, we investigated the expression
levels and therapeutic potential of DNA2 depletion in pancreatic
cancers, where 90–95% cases are associated with an activating
mutation in the K-Ras oncogene.35–37 Analysis of gene expression
patterns in pancreatic cancers in the Oncomine database
shows that DNA2 is significantly upregulated.33 Consistently, an
elevated DNA2 protein level was observed in pancreatic cancer
patient specimens (Figure 1a). Moreover, patients with chronic
pancreatitis expressed DNA2 at an elevated level in their
pancreatic tissue (Figure 1a). To establish the relationship between
the K-Ras oncogene and DNA2 expression, we analyzed a
transgenic K-RasG12D pancreatic cancer mouse model. Similar to
pancreatic cancer patient specimens, the DNA2 protein level was
greatly increased in K-RasG12D-activated early pancreatic cancer
lesions, suggesting that DNA2 overexpression is an early event
during tumorigenesis (Figure 1b). Importantly, the depletion of
DNA2 impaired the growth and survival of cells from two
pancreatic cancer lines, and also led to increased senescence
and apoptosis of these cells (Figure 1c, Supplementary Figure S1a).
Consistent with in vitro cell culture findings, DNA2 knockdown
significantly reduced tumor growth in the xenograft model
(Supplementary Figure S1b). Furthermore, our analyses showed
increased staining of p-CHK1, a key molecule in DNA damage
signaling, and reduced staining of Ki67, a marker of cell
proliferation, in DNA2-depleted cells is likely due to endogenous
DNA damage (Supplementary Figure S1c). Thus, DNA2 over-
expression is a common theme in many cancer types including
pancreatic cancer and inhibition of DNA2 reduces pancreatic
cancer cell survival both in vitro and in vivo.
Isolation of yDna2 inhibitors
We have presented evidence that DNA2 overexpression alleviates
the impaired proliferation of U2OS and MCF10A cells after an
activation of either H-Ras or cyclin E,33 suggesting that DNA2
could be an effective target in cancer therapy. This prompted us to
develop a simple screen for chemical inhibitors of DNA2. The
screen entailed the use of oligonucleotide (dT)30 having a reporter
fluorescent moiety, 6-FAM on the 5′ end, and the dark quenching
group, Iowa Black FQ, on the 3′ end. In addition, a second dark
quencher ZEN was placed between the 9th and 10th base
(Figure 2a). The fluorescence emitted by 6-FAM is quenched by
FRET, but it increases when DNA is degraded by Dna2. In the initial
screen, compounds were tested at a fixed concentration of
inhibitors (33.33 μM) with a subsaturating amount (0.09 nM) of
Dna2. The inhibitory activity of the compounds was determined
as a reduction in fluorescent signal compared with the
dimethylsulfoxide (DMSO) only control. The primary screen hits
were selected based on a ⩾ 50% inhibition of the Dna2 activity.
We screened ~ 50 000 chemical compounds from six different
libraries (Supplementary Table S1) to identify chemical inhibitors
of the Dna2 nuclease activity. As we could not purify hDNA2 in
amounts sufficient for a high-throughput screen, the initial screen
was performed with yDna2, followed by testing top candidate
compounds with hDNA2. The DNA2 nuclease domain is well
conserved among eukaryotes, and therefore we reasoned that
inhibitors of yDna2 will likely also work with the human
counterpart. DNA2 nuclease efficiently cleaves the single-stranded
DNA substrate used here (Figure 2b and Stewart et al.38), and
inhibitors are expected to block substrate cleavage. First, we
determined the concentration of yDna2 and hDNA2 and of the
control T5 nuclease needed to generate maximum fluorescence
(Figure 2c), and we optimized the screen reaction (Z′ value of 0.8)
in a robotic system with a 384-well plate setup to provide high
throughput. The first screening round identified 184 compounds,
corresponding to a hit rate of ~ 0.4%. These compounds were
subject to re-screening to confirm their efficacy and also to
eliminate those compounds that also inhibit T5 nuclease. We were
able to narrow yDna2-specific candidate compounds down to 39
(Supplementary Table S2).
We note that a number of the compounds listed in
Supplementary Table S3 inhibited the activity of both yDna2
and T5 and are therefore nonspecific. Interestingly, many of these
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nonspecific inhibitors interact with DNA and are already used in
cancer therapy, including multiple drugs known to inhibit type II
topoisomerases (for example, daunorubicin, doxorubicin and
mitoxantrone). Here, we have provided evidence that these
compounds also affect the activity of Dna2. Thus, in addition to
inducing DSBs by blocking topoisomerase II, it is likely that
these drugs affect the processing and repair of these DSBs by
nucleases.
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Cellular screen for the most potent DNA2 inhibitors
The biological effectiveness of the 39 compounds selected by
re-screening was determined by measuring their half maximal
inhibitory concentration (IC50) biochemically and in a cell-based
system using the 384-well platform (Supplementary Table S2). We
used the cancer cell line, U2OS, as cells of this lineage overexpress
DNA2 significantly and are sensitive to partial DNA2 depletion.33
We conducted the viability assay in duplicate on three separate
occasions using a concentration range of 10 pM to 10 μM for each
compound. Cell proliferation was determined using 4,6-diamidino-
2-phenylindole staining and microscopy. About 10 compounds
showed IC50 values between o1 and 10 μM both in cells and
in vitro (Supplementary Table S2), and two of them, NSC-5195242
and NSC-105808 (Figures 3a and b), were selected for further
analysis.
Inhibitory effect of NSC-5195242 and NSC-105808 on hDNA2
The initial inhibitor screen was done with yDna2, thus it was
important to test whether NSC-5195242 and NSC-105808 would
affect the activity of hDNA2. hDNA2, purified as described,39 was
first tested using the triply labeled substrate as above (Figure 2a).
We found a similar inhibitory effect on hDNA2 and comparable
IC50 values as determined for yDna2 (Figure 3c). Furthermore, we
tested the impact of these two compounds in a reconstituted 5′
DNA end resection assay including hDNA2, Bloom syndrome and
Replication protein A (RPA) as described39 and in 5′ flap
processing by hDNA2. Both compounds inhibited resection in
the reconstituted system (Figure 3d) and also 5′ flap processing
(Supplementary Figure S2). Considering that compound
NSC-105808 shows a lower IC50 in vitro and biologically, further
tests were focused on this compound. We found that NSC-105808
has no effect on ATPase activity of DNA2, nor the ability of Bloom
syndrome to unwind DNA, nor does it affect DNA binding by
DNA2 (Supplementary Figure S2). Furthermore, NSC-105808 does
not inhibit the nuclease activity of EXO1 (Supplementary
Figure S2), which can also catalyze DNA ends resection. Together,
these data provide further evidence that NSC-105808 specifically
inhibits the nuclease activity of DNA2.
NSC-105808 interferes with DNA end resection and HR in cells,
and suppresses the cisplatin sensitivity of FANCD2− /− cells
To test whether NSC-105808 inhibits proliferation of U2OS cells
by targeting DNA2, we first examined whether the ectopic
overexpression of DNA2 could reduce the negative effect of
Figure 2. Assay optimization for high-throughput screen for DNA2 inhibitors. (a) Graphical representation of the screen assay. The 30
nucleotides long ssDNA substrate is labeled with three dyes: a fluorophore (6-FAM) at the 5′end, and two dark quenchers, internal ZEN
(between 9th and 10th base) and Iowa Black FQ at the 3′ end. The extent of the reaction was determined by measuring increase of
fluorescence at wavelength of 520 nm. (b) hDNA2 (0, 0.5 or 1 nM) was incubated with radiolabeled ssDNA (2.5 nM). The radiolabel is denoted
by *. (c) Degradation of triply labeled ssDNA (100 nM) by yDna2 (0.002 to 5.0 nM), hDNA2 (0.00016 to 166 nM) and T5 nuclease (0.01–10 units).
Figure 1. DNA2 is overexpressed in pancreatic cancer lesions. (a) Immunohistochemistry (IHC) staining of DNA2 in representative human
pancreatic lesion specimens. Two cases are presented and the lesions (boxed) are also shown at a higher magnification. (i, ii) normal
pancreatic tissue; (iii, iv) hyperplasia in pancreatic tissue with chronic pancreatitis; (v, vi) pancreatic carcinoma. (b) IHC staining of DNA2 in
wild-type mouse pancreatic tissue (top) and in LSL-K-RasG12D mouse pancreatic cancer tissue (bottom). Scale bar, 100 μm. Segments (boxed) of
the images are also shown at a high magnification. (c) DNA2 depletion affects the survival of pancreatic cancer cells. Pancreatic cancer cell
lines AsPC-1 and PANC-1 were stably transfected with short hairpin RNA (shRNA) vectors against two non-overlapping sequences in DNA2 or
scramble control (Mock) (see also Supplementary Figure S1). (Left) Clonogenic assay, cell survival scored 10–15 days after seeding. (Middle)
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, cells proliferation measured 72 h after seeding. (Right) Senescence
assay with β-galactosidase staining and apoptosis assay using annexin V staining performed 72 h after DNA2 knockdown. Each value
represents the mean± s.e.m. from three independent experiments (*Po0.05; **Po0.01; ***Po0.005; ****Po0.001).
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NSC-105808 on cell growth. An approximately 1.5–2.0-fold
increase in DNA2 protein level was able to attenuate the negative
impact of NSC-105808 on cell proliferation, supporting the idea
that DNA2 is the target of NSC-105808 in cells (Supplementary
Figure S3). DNA2 functions in DSB end resection and HR,17,18,33
thus we asked whether NSC-105808 interferes with these
biological processes. Similar to DNA2 knockdown, NSC-105808
(24-h treatment) significantly reduced DSB repair by gene
conversion or single stand annealing as determined by using
two green fluorescent protein-based reporter assays (Figure 4a,
Supplementary Figures S4-6 and Peng et al.33). The treatment with
NSC-105808 had only a mild impact on cell cycle distribution at
Figure 3. Validation of the top two inhibitors identified from the high-throughput screen. (a) Chemical structure of NSC-5195242
(2-nitrophenanthrene-9,10-dione) and NSC-105808 (6-amino-7-bromoquinoline-5,8-dione). (b, c) Dose-response curves for indicated
compounds, cell based (U2OS cell line) (b) and in vitro (c). The IC50 value and the protein concentration used are indicated. Triple labeled
substrate (0.1 μM) as in Figure 2a was used. The concentration range of inhibitors was 0.003–666.67 μM. (d) Degradation of radiolabeled 2-kb
dsDNA (0.5 nM ends) with hDNA2 (5 nM), Bloom syndrome (5 nM) and RPA (100 nM) and the indicated concentrations of NSC-5195242 and
NSC-105808. The asterisks denote the radiolabel. Plotted are the average data from three independent experiments and the error bars
represent 1 s.d.
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the highest tested concentration (0.6 μM) with a slight decrease of
G1 and increase of G2 cells, but with no impact on the cellular
level of DNA2 protein (Supplementary Figures S7 and 8). We note
that longer (448 h) exposure to NSC-105808 causes cell death
(Figure 3b). To test DSB end resection, we followed phosphoryla-
tion of the single-stranded DNA (ssDNA)-binding protein RPA (p-
RPA) as described previously.40 Cells were treated with the
topoisomerase I inhibitor camptothecin, which induces DNA nicks,
reversed replication forks and single-ended DSBs. As shown in
Figure 4b, NSC-105808 treatment significantly attenuated the
accumulation of camptothecin-induced p-RPA, suggesting an
impairment of DSB end resection. We then confirmed this result
by conducting chromatin fractionation and observed that
NSC-105808 reduced p-RPA accumulation in the chromatin
fraction with a concomitant enhancement in the γ-H2AX level,
reflective of an accumulation of unrepaired DSBs (Figure 4c).
Altogether, the above results provide evidence that NSC-105808
interferes with DSB resection and HR in cells.
We wished to further verify the DNA2 specificity of NSC-105808
in cells. Previous work revealed that DNA2 depletion in FANCD2-
deficient cells partially suppresses the sensitivity of these cells to
cisplatin.41 As shown in Figure 4d, FANCD2− /− cells were more
sensitive to cisplatin treatment compared with control cells,
and, importantly, a very low concentration of NSC-105808
lessened the cisplatin sensitivity of these cells. Together, our
results are consistent with the premise that DNA2 is the target of
NSC-105808 in cells.
Oncogene induction renders cells susceptible to NSC-105808
DNA2 overexpression, often observed in cancer cells, has
been proposed to alleviate oncogene-induced replication stress.
Increased sensitivity of cancer cells to DNA2 depletion33 can likely
be explained by an increased amount of substrates that are
processed by DNA2 nuclease/helicase. We therefore asked
whether NSC-105808 can sensitize cancer cells to oncogene-
Figure 4. NSC-105808 inhibits HR repair and DSB end resection. (a) Analysis of HR efficiency with the DR-green fluorescent protein (GFP) assay.
Representative images of flow cytometry analysis and bar graph showing percentage of GFP cells from at least three independent
experiments. Each value represents the mean± s.d. (b, c) Analysis of RPA phosphorylation in U2OS cells treated with NSC-105808 (2 h, 0.3 μM)
and/or camptothecin (CPT; 2 h, 1 μM). (b) Representative images of cells subjected to immunofluorescent staining of p-RPA and bar graph
showing percentage of cells with positive p-RPA staining from three independent experiments. Each value represents the mean± s.d.
(c) Western blot analysis of chromatin fraction with the indicated antibodies. (d) Analysis of colony formation by FANCD2 (+/+) and
FANCD2 (− /− ) cells treated with cisplatin and/or NSC-105808. Each value is relative to the untreated control group of each cell line. The
graph represents the mean± s.e.m. from three independent experiments. *Po0.01.
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induced replication stress. Initially, we compared the impact of our
DNA2 inhibitor in pancreatic or breast cancer cells versus control
cells (Figures 5a and b). Transformed pancreatic cancer cell lines
(AsPC-1, PANC-1) were more sensitive to NSC-105808 when
compared with non-transformed pancreatic ductal epithelial cells
(DT-PD59). Similarly, transformed breast cancer cells (Hs578T and
BT549) were more sensitive than MCF10A non-transformed breast
epithelial cells to the DNA2 inhibitor.
Three separate cell models were then used to test whether
NSC-105808 can target cancer cells with oncogene activation
(Figures 5c-e). First, we generated an MCF10A cell line, an immor-
talized non-transformed breast epithelial cell line, with inducible
H-Ras expression. Induction of H-Ras expression is shown in
Supplementary Figure S9a. Upon activation of H-Ras, cells
exhibited increased sensitivity to the DNA2 inhibitor (Figure 5c).
Second, we used the E6/E7 oncoprotein to induce replication
stress in non-transformed pancreatic ductal cells (DT-PD59) as
previously described.42 Again, sensitivity to NSC-105808 was
higher in cells with oncoprotein-induced replication stress
(Figure 5d). In addition, we also established an inducible K-Ras
expression cell line using non-transformed pancreatic ductal
epithelial cells (Supplementary Figure S9a). Both 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony
formation assays showed that activation of K-Ras expression
sensitized pancreatic ductal epithelial cells to NSC-105808
treatment (Supplementary Figures S9b and 9c). Finally, we tested
a series of epithelial cell lines that represent different stages of
breast cancer progression:43 control non-tumorigenic MCF10A
cells; premalignant/tumorigenic MCF10AT1 cells, derived from
MCF10A cells by the expression of oncogenic H-Ras; tumorigenic/
locally invasive MCF10-DCIS cells, and tumorigenic/metastatic
MCF10CA1a cells, cloned from xenograft lesions induced by
premalignant MCF10AT1 cells. Consistent with other observations,
the three cell lines with oncogene activation were more sensitive
to DNA2 inhibitor treatment compared with the MCF10A control
(Figure 5e). Thus, in different cell models, oncogene activation
sensitizes cells to NSC-105808.
DISCUSSION
During tumorigenesis, the activation of an oncogene or loss of a
tumor-suppressor gene leads to excessive growth signals and
replication stress. Notably, about 30% of all cancers have an
activating mutation in Ras and the vast majority (up to 95%) of
pancreatic cancer patients harbor a mutation in K-Ras.35–37
Unfortunately, thus far, no effective inhibitor of the K-Ras
oncoprotein has reached the clinic. In this study, we have strived
to test the efficacy of DNA2 nuclease inhibition in cancer cells that
experience oncogene-induced replication stress. As such stress is a
common denominator among multiple cancer types, DNA2
inhibition could be an efficacious strategy to treat a broad
spectrum of cancers. Besides targeting cancer cells with an
activated oncogene, chemical inhibition of DNA2 may also be
useful for sensitizing cells to DNA damage when combined with
radiomimetic chemotherapy or radiation therapy. As we expected,
recent studies reported that DNA2 inhibition can sensitize breast
cancer cells to chemotherapy inducing DNA damage.44 We
developed a simple high-throughput screening assay for DNA2
inhibitors, which can screen compound collections in very small
reaction volume and in general to screen for inhibitors of other
nucleases. We identified several compounds with the ability to
inhibit DNA2 in DNA incision and also in a reconstituted system of
DNA end resection. The NSC-105808 compound inhibits DNA2
but not other tested nucleases, however, additional cellular
targets cannot be excluded. Importantly, NSC-105808 treatment
recapitulates several phenotypes of cells with DNA2 depletion,
such as attenuated DSB end resection, decreased HR and
suppression of the sensitivity of FANCD2-deficient cells to
cisplatin.41 DNA2 has an important role in telomere replication,45
thus the effect of NSC-105808 on telomere stability cannot be
excluded. The inhibitor reduces the growth of various cancer cells,
and specifically those cells in which replication stress is induced
via oncogene activation. A similar range of IC50 values for the
NSC-105808 in vivo and in in vitro assay may indicate that even
minimal inhibition of DNA2 in cells could be lethal to cells. For
Figure 5. Oncogene induction enhances sensitivity of cancer cells to NSC-105808. (a-e) Graphs showing proliferation of indicated cell lines in
response to a 48-h treatment with the indicated concentrations of NSC-105808. Proliferation relative to cells treated with vehicle alone was
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Each value represents the mean± s.e.m. from
three independent experiments. (a) Proliferation of control pancreatic epithelial cells DT-PD59 and transformed pancreatic cancer cells AsPC-1
and PANC-1. (b) Proliferation of normal breast epithelial cells MCF10A and breast cancer cells Hs578T and BT549. (c) Proliferation of MCF10A
cells with or without H-Ras expression. H-Ras was induced with doxycycline (2 μg/ml). (d) Proliferation of control pancreatic DT-PD59 cells
and transformed DT-PD77 cells with E6/E7 oncoprotein activation. (e) Proliferation of MCF10A breast cells without and with H-Ras activation
(AT1, DCIS, CA1a).
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example, a single unrepaired DSB is lethal for cells. Alternatively
DNA2 sensitivity to the drug can be altered by cell-specific
features, such as DNA2 posttranslational modifications. Together
our work suggests that temporary inhibition of DNA2 nuclease
represents a promising strategy in cancer therapy.
MATERIALS AND METHODS
Human cell cultures
U2OS and MCF10A cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and were maintained in McCoy’s 5A
medium supplemented with 10% fetal bovine serum. MCF10A cells were
cultured in mammary epithelial growth medium containing insulin,
hydrocortisone, epidermal growth factor and bovine pituitary extract
purchased from Clonetics (Lonza Group Ltd, Basel, Switzerland). MCF10A
cells with stable H-Ras expression were generated by infection with
lentiviral inducible-V5 construct (Life Technologies, Grand Island, NY, USA)
and maintained in the presence of G418 (200 μg/ml) and blasticidin (4 μg/
ml). AsPC-1 and PANC-1 cells were cultured in Dulbecco's modified Eagle's
medium (Corning Cellgro, Manassas, VA, USA) with 10% fetal bovine
serum, vitamin (100× ), non-essential amino acids (100 × ) and Penicillin/
Streptomycin (100 × ). BT549 cells were cultured in RPMI-1640 medium
with 0.023 IU/ml insulin and Hs578T cells in Dulbecco's modified Eagle's
medium medium with 0.01 mg/ml bovine insulin. The pancreatic cell lines
(DT-PD59, DT-PD77-E6/E7) were kindly provided by Dr Michel J Quellette
(University of Nebraska Medical Center, Omaha, NE, USA) and cultured as
described.46 Pancreatic ductal epithelial cells with inducible K-Ras
expression were generated and maintained in the Keratinocyte-SFM
medium (Life Technologies) as previously described.47 A series of breast
epithelial cell lines transformed by H-Ras (MCF10A, MCF10AT1, MCF10-
DCIS and MCF10CA1a) were obtained from Dr Isabelle Bedrosian
(Department of Surgical Oncology, MD Anderson Cancer Center, Houston,
TX, USA) and maintained as described.43 In the experiments described in
Figures 5b and c, MCF10A cells were obtained from ATCC. FANCD2− /−
and control cell lines were obtained from Dr Randy Legerski (Department
of Genetics, MD Anderson Cancer Center). Cells were maintained in
Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal
bovine serum and 1% penicillin/streptomycin at 37 °C in 5% CO2. All cell
lines were validated by short tandem repeats DNA fingerprinting using the
AmpF short tandem repeats Identifiler kit according to the manufacturer
instructions (Applied Biosystems, Foster City, CA, USA; cat. # 4322288). The
short tandem repeats profiles were compared with known ATCC
fingerprints, to the Cell Line Integrated Molecular Authentication database
(CLIMA) and to the MD Anderson fingerprint database. The short tandem
repeats profiles matched known DNA fingerprints or were unique.
Plasmids, short hairpin RNA and transfection
The pLenti6.3/TO/V5-H-Ras vector was obtained from Dr Shiaw-Yih Lin
(Department of Systems Biology, MD Anderson Cancer Center). Briefly,
PCMV-H-RAS (V12) was purchased from Invitrogen (Waltham, MA, USA)
and subcloned into the pLenti6.3/TO/V5-DEST vector (Invitrogen) based on
the commercial protocol of ViraPower TM HiPerform TM T-Rex TM Gateway
Expression system (Thermo Fisher Scientific Waltham, MA, USA). pLenti3.3/
TR and pLenti6.3/TO/V5-H-Ras were stably integrated into MCF10A cells.
Expression of H-Ras was induced by the addition of doxycycline (1 μg/ml)
for 48 h. The vector that expresses FLAG-tagged DNA2 has been
described.33 DNA2 short hairpin RNA vectors and control short hairpin
RNA vectors against luciferase sequences were obtained from Sigma (St
Louis, MO, USA; shDNA2#1: 5′-CCGGACCTGGTGTTGGCAGTCAATACTCGAGT
ATTGACTGCCAACACCAGGTTTTTTTG-3′; shDNA2#2: 5′-CCGGAGTTTGTGATG
GGCAATATTTCTCGAGAAATATTGCCCATCACAAACTTTTTTTG-3′). On-target
smart pool small interfering RNAs against DNA2 were purchased from
Dharmacon Research (Lafayette, CO, USA; #9: 5′-AGACAAGGUUCCA
GCGCCA-3′; #10: 5′-UAACAUUGAAGUCGUGAAA-3′; #11: 5′-AAGCACAGG
UGUACCGAAA-3′; #12: 5′-GAGUCACAAUCGAAGGAUA-3′). Transfection of
plasmids was performed with the FuGENE 6 reagent from Roche
(Indianapolis, IN, USA). Transfection of small interfering RNAs was
performed with Oligofectamine (Invitrogen).
Immunohistochemical staining
Tissue microarrays of formalin-fixed, paraffin-embedded pancreatitis,
pancreatic tumors with their corresponding nonneoplastic tissues were
obtained from US Biomax (Rockville, MD, USA). Formalin-fixed, paraffin-
embedded slides of a conditional LSL-K-RasG12D/transgenic pancreatic
cancer mouse model was obtained from Dr Chinthalapally Rao (Depart-
ment of Internal Medicine, University of Oklahoma, Oklahoma City, OK,
USA). After slides were deparaffinized with xylene and rehydrated with
ethanol, antigen retrieval was carried out by placing the slides in 0.1 M
sodium citrate (pH 6.0) in a water bath for 30 min at 95 °C. Endogenous
peroxidase activity was quenched with 3% hydrogen peroxide in
phosphate-buffered saline for 10 min. Slides were washed three times
with phosphate-buffered saline and incubated in blocking buffer contain-
ing 10% goat serum for 30 min. The slides were incubated with DNA2
antibody (1:200) overnight at 4 °C in a wet box, and immunohistochemical
staining was done by using the Vectastain ABC avidin biotin-peroxidase
enzyme complex kit (Vector Laboratories, Burlingame, CA, USA). Slides
were counterstained with hematoxylin and mounted with Permount
aqueous medium.
Cell proliferation assay
Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (Sigma) reduction (Supplementary
Materials and Methods).
Colony-forming assay
Transfection and colony-forming assay were performed as previously
described33 (Supplementary Materials and Methods).
Senescence assay
The assay was performed with a senescence β-galactosidase staining kit
(#9860; Cell Signaling, Danvers, MA, USA) according to the manufacturer’s
protocol (Supplementary Materials and Methods).
Flow cytometric analysis of apoptosis and BrdU incorporation
Apoptosis was measured by flow cytometry using the Annexin V FITC assay
kit based on the protocol from the manufacturer (Invitrogen). For BrdU
(bromodeoxyuridine (5-bromo-2′-deoxyuridine)) analysis, after treatments,
cells were labeled with BrdU (Sigma) for 30 min before fixation with 70%
cold ethanol (−20 °C). The next day, cells were washed with cold
phosphate-buffered saline and incubated with 2 M HCl for 5 min at room
temperature. After adjusting the pH with 0.1 M sodium borate (pH 8.5), cells
were incubated in 1% bovine serum albumin with 0.1% Triton X-100 for
30 min and mouse anti-BrdU antibody (1:400) for 1 h to detect BrdU
labeling. After washing, cells were incubated with secondary antibody
(fluorescein isothiocyanate 1:400) for 30 min. Cells were resuspended in
staining solution (10 μg/ml propidium iodide, 20 μg/ml RNase A and 0.05%
Triton X-100) and cell cycle analysis was performed at the MD Anderson
Cancer Center Flow Cytometry and Cellular Imaging Facility. For
fluorescence-activated cell sorting analysis, the percentage of cells with
positive BrdU staining in each phase of the cell cycle was quantitated with
the CellQuest software and ModFit software (Verity Software House Inc.,
Topsham, ME, USA).
Gene conversion and single stand annealing repair assays
The DR-green fluorescent protein, pCAGGS and pCBASce plasmids were
kindly provided by Dr Maria Jasin (Memorial Sloan-Kettering Cancer
Center, New York, NY, USA). U2OS cells containing a single copy of the HR
repair reporter substrate DR-green fluorescent protein were generated as
previously described.48 Single stand annealing reporter cells were kindly
provided by Dr Jeremy Stark (Beckman Research Institute of the City of
Hope, Duarte, CA, USA).49 Details in Supplementary Materials and Methods.
Immunofluorescent staining and chromatin fractionation
For the detection of DNA damage-induced p-RPA34 (S4/S8), immuno-
fluorescent staining, and the preparation of chromatin fractions and
western blot analyses were performed as described previously.33,48
High-throughput screen for inhibitors of DNA2
The screen entailed the use of oligonucleotide (dT)30 having a
reporter fluorescent moiety, 6-FAM (excitation max. = 494 nm, emission
max. = 520 nm) on the 5′ end, and the dark quenching group, Iowa Black
FQ (absorption max. = 531 nm), on the 3′ end. In addition, a second dark
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quencher ZEN (N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine,
absorption max. = 532 nm) is placed between 9th and 10th base
(Figure 2a). Initial screen, it was performed with yDna2.22 Then, the
top candidate compounds were tested on hDNA2. Identical reaction
conditions were used for assaying the nuclease activity of yDna2 and
hDNA2. We note that yDna2 is more active on the ssDNA substrate than
hDNA2, thus the experiment with ssDNA substrates were done with 10 nM
of hDNA2. The reaction buffer was 20 mM HEPES/NaOH, pH 7.5, 60 mM KCl,
1 mM DTT, 100 μg/ml bovine serum albumin and 0.05% Triton X-100. The
nuclease assay was initiated by adding MgCl2 (3 mM final concentration).
T5 nuclease was assayed in the buffer (50 mM potassium acetate, pH 7.9,
20 mM Tris-acetate, 10 mM magnesium acetate and 1 mM DTT) provided by
the vendor (NEB, Ipswich, MA, USA). The concentration of the fluorogenic
substrate was 0.1 μM. The optimal amount of yDna2, hDNA2 and T5
nuclease was determined by utilizing the Kaleidagraph software (Reading,
PA, USA) to fit the data according to Michaelis Menton Kinetics
(V = V0+Vmax*x/(Km+x)). For curve fitting, the maximum increase in
fluorescence (upon adding 5 nM of yDna2 or 166 nM of hDNA2 or 10 units
of T5 nuclease) corresponds to Vmax, the background fluorescence (without
enzyme) corresponds to V0 and ‘x’ is the enzyme concentration (nM). All
the compounds were dissolved in DMSO and DMSO alone was used as
control; the final concentration of DMSO was at 3.33% for protein-based
assay and 0.1% for cell-based assay. The Z’ value was calculated as
previously described.50 Cell proliferation was determined using 4,6-
diamidino-2-phenylindole staining followed by high-throughput micro-
scopy in a 384-well plate setup. In brief, cells were fixed with
formaldehyde, washed and stained with 4,6-diamidino-2-phenylindole
and the number of nuclei in each well counted by automated microscopy.
The data were analyzed as described.51
Nuclease substrates
The oligonucleotide PSOL6929 (5′-TTCATGGCTTAGAGCTTAATTGCTGAA
TCT-3′) was 5′ end-labeled with γ32P-ATP (Perkin-Elmer, Waltham, MA,
USA) and T4 polynucleotide kinase (NEB). The 2-kb dsDNA substrate is a
fragment of the hDNA2 gene created by PCR with oligonucleotides
PSOL4642 (5′-GATCCTCTAGTACTTCTC-3′) and PSOL6134 (5′-TCTACCT
CAAGACTGGTCAG-3′) using the DNA2 expression vector pJD7239 as
template; 50 μCi of α32P-dCTP (Perkin-Elmer) was included in the reaction
to randomly radiolabel the PCR fragment.
Nuclease assays
Nuclease assays were performed in buffer R (20 mM Na-HEPES pH 7.5, 1 mM
ATP, 0.1 mM DTT, 100 μg/ml bovine serum albumin, 0.05% Triton X-100,
2 mM MgCl2, 100 mM KCl) and contained 0.5 nM ends (2-kb substrate) or
5 nM ends (the ssDNA oligonucleotide PSOL6929) of DNA. Reactions
containing Bloom syndrome also included an ATP regenerating system
consisting of 10 mM creatine phosphate and 50 μg/ml creatine kinase. In
control reactions, DMSO was used in place of the inhibitor. Reactions with
DNA2 alone were incubated at 30 °C, and those with DNA2-Bloom
syndrome-Replication protein A and EXO1 were incubated at 37 °C for the
indicated times. After the addition of sodium dodecyl sulfate to 0.02%,
proteinase K to 0.25 μg/μl, and 0.08% Orange G dye with a final glycerol
concentration of 10%, the reaction mixtures were incubated for 5 min at
37 °C. Electrophoresis was done in native 10% polyacrylamide gels in
Tris-borate-EDTA buffer (ssDNA substrate) or in 1% agarose gels in
Tris-acetate-EDTA buffer (40 mM Tris-acetate, pH 7.4, 0.5 mM EDTA) (2 kb
substrate). Gels were dried onto DEAE paper on top of Whatman filter
paper (GE, Issaquah, WA, USA) and then analyzed in a BioRad Personal
Molecular Imager FX phosphorimager. Band intensity was quantified using
Image Lab software (Bio-Rad, Hercules, CA, USA). The fraction of DNA
substrate digested was determined by measuring the amount of substrate
remaining and normalizing to the total substrate in the negative control
lane containing no protein.
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